This summer I'm living in Japan, uniquely positioning me to observe some of the key metrics for ESGs through a global lens. This article will be part one of a multi part series covering ESG funds … [Read more...] about Global ESG Portfolios: Part 1
Happy Friday everyone! The end of the Q2 is nearly upon us (June 30th). Going into the 2nd half of the year I want to present for our members up and coming companies on the path to success. In my last … [Read more...] about An Intriguing Play In Immune-Oncology For Summer 2019
The four qualities that I assign the most weight when evaluating a biotech company for viability is 1) An efficacious product 2) Sufficient funding 3) Competent leadership and 4) Relationships with … [Read more...] about My #1 Mid-Cap Biotech Stock Pick For 2019
In the field of oncology, historical numbers suggest only 32.7% of phase 2 trials move on to phase 3. Furthermore, this data suggest that the chance of a phase 2 trial turning out successful and … [Read more...] about Why I am Waiting to Buy this Company as their Data Readout Approaches
Last week the markets found its footing after a sharp sell-off in May. Looking at our MS Performance Tracker it appears that tech rebounded marginally more than biotech, and on par with the rest of … [Read more...] about Biopharma Stock Watch June 10th-14th
ADMA Biologics (Nasdaq: ADMA), an innovator in the manufacturing and sale of intravenous immunoglobulin (IVIG) medicine, delivered a 23 minute presentation June 6th at the Jefferies 2019 Healthcare … [Read more...] about A Look At ADMA Biologics Investor Presentation At Jefferies 2019 Healthcare Conference
Background Today one of our top picks for 2019 "ADMA" saw significant downside after news of Purcell Julie & Leftowitz LLP intention to investigate ADMA for "potential breaches of fiduciary … [Read more...] about Are Law Firms Unfairly Targeting Biotech?
Tech Giant Slack is set to IPO through a direct listing this month. It will be trading under the symbol "SK" and marks the continuation of multi billion dollar valued tech giants going public with … [Read more...] about Slack Direct Listing, Gold Mine Or Money Pit?
The past two months have been eventful for my number one stock pick ADMA Biologics (Nasdaq: ADMA). Moreover, on Friday May 24th, 2019 I added a new stock to the MS portfolio- Regenxbio (Nasdaq: RGNX). … [Read more...] about Portfolio Update: ADMA Biologics
Background We recently covered Uber and some of the headwinds they are facing. Since this research was released, few to none of the headwinds have been adequately addressed and the share price has … [Read more...] about UBER Update